Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Strunc

Neurology with Special Qualifications in Child Neurology Norfolk, VA Medical Doctor

NPI 1427013036 CMS profile 110166

601 Childrens Ln, Norfolk, VA 23507

Open in the dashboard

General payments

$639,266

773 records reported · program years 2019–2025

Research payments

$3,360

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$366,244 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Michael Strunc of Norfolk, VA is reported in the CMS Open Payments database as having received $639,266 across 773 general payments and $3,360 in research payments paid to them. Separately, studies naming them as principal investigator received $366,244 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $104,062 144
2024 General $123,892 132
2023 General $79,485 124
2022 General $115,814 146
2022 Research $3,360 2
2021 General $95,900 85
2020 General $41,480 44
2019 General $78,633 98

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Strunc
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Michael Strunc were reported at $104,062. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Michael Strunc Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $78,633 $262 $68–$1,313 $163
2020 $41,480 $188 $46–$1,222 $114
2021 $95,900 $183 $45–$1,356 $132
2022 $115,814 $229 $72–$1,177 $149
2023 $79,485 $269 $93–$1,195 $160
2024 $123,892 $300 $98–$1,428 $164
2025 $104,062 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Jazz Pharmaceuticals Inc. $439,832 498 payments
  2. Neurelis, Inc. $76,353 95 payments
  3. Avadel CNS Pharmaceuticals, LLC $65,264 74 payments
  4. Harmony Biosciences LLC $36,406 37 payments
  5. Axsome Therapeutics, Inc. $11,885 9 payments
  6. UCB, Inc. $5,895 33 payments
  7. LivaNova USA, Inc. $2,994 16 payments
  8. Supernus Pharmaceuticals, Inc. $279 6 payments
  9. Novartis Pharmaceuticals Corporation $117 1 payment
  10. Sunovion Pharmaceuticals Inc. $116 1 payment
  11. Other $125 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $426,878 161 payments
  2. Consulting Fee $84,701 37 payments
  3. Travel and Lodging $70,012 277 payments
  4. Honoraria $34,078 12 payments
  5. Food and Beverage $16,798 280 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $6,500 3 payments
  7. Education $300 3 payments
Products named General payments · program years 2019–2025
  1. XYWAV $275,400 313 payments
  2. XYREM $90,848 121 payments
  3. VALTOCO $76,353 95 payments
  4. LUMRYZ $65,264 74 payments
  5. SUNOSI Neurology $54,471 43 payments
  6. WAKIX Narcoplepsy $18,581 12 payments
  7. WAKIX Narcolepsy $17,471 15 payments
  8. SUNOSI Pain $16,427 15 payments
  9. Sunosi Neurology $11,838 8 payments
  10. Fintepla $5,015 9 payments
  11. Other $4,774 64 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Neurelis, Inc. $3,360 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

78

Median for Neurology: 833

Drug cost

$111,536

Median for Neurology: $202,670

Branded share of claims

35.9%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Epidiolex Cannabidiol (Cbd) Brand 12 $84,949
Valtoco Diazepam Brand 16 $21,260
Fluoxetine Hcl Generic 24 $2,292
Risperidone Generic 11 $1,820
Oxcarbazepine Generic 15 $1,215

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XYWAV
$60,208 — —
LUMRYZ
$32,063 — —
WAKIX
$18,581 — —
VALTOCO
$10,360 16 —
Sunosi
$2,037 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

775 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record